EMA/623412/2020

European Medicines Agency decision

P/0455/2020

of 4 December 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral for cefepime / taniborbactam (EMEA-002576-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0455/2020

of 4 December 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral for cefepime / taniborbactam (EMEA-002576-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Venatorx Pharmaceuticals, Inc. on 12 August 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 October 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for cefepime / taniborbactam, powder for concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for cefepime / taniborbactam, powder for concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Venatorx Pharmaceuticals, Inc., 74 E. Swedesford Road, Suite 100, Pennsylvania, 19355 - Malvern, United States.

EMA/PDCO/425104/2020
Amsterdam, 16 October 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-002576-PIP01-19

Scope of the application

Active substance(s):

Cefepime / taniborbactam

Condition(s):

Treatment of gram-negative bacterial infections

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Venatorx Pharmaceuticals, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Venatorx Pharmaceuticals, Inc. submitted for agreement to the European Medicines Agency on 12 August 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 17 September 2019.

Supplementary information was provided by the applicant on 13 July 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of gram-negative bacterial infections

2.1.1. Indication(s) targeted by the PIP

Treatment of complicated urinary tract infections (cUTI) including acute pyelonephritis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	**Number of measures**	**Description**
Quality-related studies	2	Study 1 Compatibility and stability of the solution for infusion at drug concentrations applicable to paediatric patients from 34 weeks post menstrual age (PMA). Study 2 Age-appropriate dosage form for parenteral use
Non-clinical studies	2	Study 3 Dose range-finding toxicity study in juvenile rats Study 4 Definitive juvenile toxicity study
Clinical studies	2	Study 5 Open-label study to characterize the pharmacokinetics of cefepime/taniborbactam in paediatric patients from 34 weeks post-menstrual age (PMA) to less than 6 years of age who are receiving systemic antibiotic therapy for the treatment of a confirmed or suspected bacterial infection.

Area	Number of measures	Description
		Study 6 Randomized, open-label, active comparator study to assess pharmacokinetics, safety and tolerability of cefepime/taniborbactam in paediatric patients from 34 weeks PMA to less than 18 years of age.
Extrapolation, modelling and simulation studies	2	Study 7 Population Pharmacokinetic analysis Study 8 Analysis of existing in-house data, including data generated in Studies 5 and 6 to support efficacy, safety and dosing assumptions in the paediatric population based on PK extrapolation.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes